The company has entered into a Business Transfer Agreement with Group Pharmaceuticals for the acquisition on a going-concern basis. The Wellness Portfolio recorded a turnover of ₹24.6 crore in FY2025-26.
The transaction involves an initial consideration of ₹23.7 crore on closing, with additional consideration of up to ₹23 crore linked to FY2027-28 sales, subject to the total consideration being capped at ₹46.7 crore.
ALSO READ | Jagsonpal Pharmaceuticals to acquire 85% stake in Aequitas Healthcare for ₹21 crore
The acquisition is expected to be completed on or before November 1, 2026, subject to fulfilment of conditions precedent and other terms of the BTA.
Jagsonpal said the acquisition will strengthen its pharmaceutical portfolio, expand its presence across relevant therapeutic segments and enhance its market reach. The portfolio comprises identified products, assets, contracts, employees and other arrangements relating to the business, which has a presence in India.
The company said the business transfer does not fall within the purview of related party transactions. None of the promoters, promoter group or group companies has any interest in the wellness portfolio or Group Pharmaceuticals. No governmental or regulatory approvals are required for the acquisition.
Jagsonpal said it intends to integrate the acquired portfolio with its existing commercial platform and capabilities while leveraging its existing distribution network to create operating synergies.
ALSO READ | Share Buyback: A ₹1,100 crore drugmaker will be repurchasing its shares for the first time
Manish Gupta, Managing Director, Jagsonpal said, “The acquisition marks another meaningful step in our growth journey. It strengthens our pharmaceutical portfolio and expands our presence across complementary therapeutic segments, especially in women’s healthcare, while remaining consistent with our asset-light and focused approach to growth. We remain focused on pursuing opportunities that complement our existing capabilities and create sustainable, long-term value for all our stakeholders.”
Amrut Medhekar, Chief Operating Officer, Jagsonpal, said, “We are delighted to welcome this portfolio and the employees of the business into our organisation, and are fully committed to ensuring their smooth and seamless integration.
We are equally excited about this acquisition as we embark on our next phase of growth, expanding our field force, strengthening our pan-India presence and creating significant cross-selling opportunities across our portfolio. Together, we look forward to a seamless transition and unlocking the portfolio’s full growth potential by leveraging our established commercial infrastructure and strong execution capabilities.”
ALSO READ | Jagsonpal Pharma surges 12% after buyback plan of up to 16 lakh shares at ₹250 each
The transaction remains subject to applicable conditions precedent and other customary closing conditions under the BTA. Jagsonpal said Think Law Advisors represented it as its legal adviser, while Tatva Legal advised Group Pharmaceuticals on the transaction.
Jagsonpal has a pharmaceutical portfolio focused on gynaecology, orthopaedics and dermatology, according to the company. It has over 20 brands, including the top five brands in the molecule category, a pan-India presence and a sales team of over 1,000 professionals.
Shares of Jagsonpal Pharmaceuticals Ltd ended at ₹227.65, up by ₹1.75, or 0.77%, on the BSE.
ALSO READ | Buyback Alert: Shareholders of this ₹1,400 crore drugmaker approve repurchase plan; Check premium